AILT
MCID: ANG046
MIFTS: 52

Angioimmunoblastic T-Cell Lymphoma (AILT)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioimmunoblastic T-Cell Lymphoma

MalaCards integrated aliases for Angioimmunoblastic T-Cell Lymphoma:

Name: Angioimmunoblastic T-Cell Lymphoma 12 53 59 55 15
Immunoblastic Lymphadenopathy 53 59 44
T-Cell Lymphoma, Aild Type 53 59
Lymphogranulomatosis X 53 59
Angioimmunoblastic Lymphadenopathy 73
Aitl 53
Ailt 59

Characteristics:

Orphanet epidemiological data:

59
angioimmunoblastic t-cell lymphoma
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0111147
ICD10 33 C86.5
MeSH 44 D007119
NCIt 50 C7528
SNOMED-CT 68 835009
Orphanet 59 ORPHA86886
UMLS via Orphanet 74 C0020981
ICD10 via Orphanet 34 C86.5
UMLS 73 C0020981

Summaries for Angioimmunoblastic T-Cell Lymphoma

Disease Ontology : 12 A peripheral T-cell lymphoma characterized by autoimmune features and poor prognosis.

MalaCards based summary : Angioimmunoblastic T-Cell Lymphoma, also known as immunoblastic lymphadenopathy, is related to b-cell lymphomas and autoimmune lymphoproliferative syndrome, type v, and has symptoms including exanthema An important gene associated with Angioimmunoblastic T-Cell Lymphoma is BCL6 (BCL6, Transcription Repressor), and among its related pathways/superpathways are Allograft rejection and T cell receptor signaling pathway. The drugs Cyclophosphamide and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Wikipedia : 76 Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as... more...

Related Diseases for Angioimmunoblastic T-Cell Lymphoma

Diseases related to Angioimmunoblastic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
# Related Disease Score Top Affiliating Genes
1 b-cell lymphomas 30.7 BCL6 MME SYK TIA1
2 autoimmune lymphoproliferative syndrome, type v 30.5 BCL6 TIA1
3 lymphoma, hodgkin, classic 30.2 BCL6 MME
4 composite lymphoma 30.1 BCL6 GZMB TIA1
5 burkitt lymphoma 30.0 BCL6 CXCL13 MME
6 peripheral t-cell lymphoma 29.8 BCL6 CXCL13 GZMB ITK MME SYK
7 angioimmunoblastic lymphadenopathy with dysproteinemia 11.8
8 lymphoma 11.3
9 diffuse large b-cell lymphoma 10.6
10 leukemia 10.4
11 arthritis 10.3
12 pure red-cell aplasia 10.3
13 pneumonia 10.3
14 vasculitis 10.3
15 hypereosinophilic syndrome 10.3
16 plasma cell leukemia 10.3
17 heart lymphoma 10.2 BCL6 MME
18 intravascular large b-cell lymphoma 10.2 BCL6 MME
19 testicular lymphoma 10.2 BCL6 MME
20 t-cell/histiocyte rich large b cell lymphoma 10.2 BCL6 MME
21 spondyloarthropathy 1 10.2
22 leukemia, chronic lymphocytic 2 10.2
23 leukemia, chronic lymphocytic 10.2
24 rheumatoid arthritis 10.2
25 ascites, chylous 10.2
26 mycosis fungoides 10.2
27 myelofibrosis 10.2
28 polyarteritis nodosa, childhood-onset 10.2
29 follicular lymphoma 10.2
30 hemophagocytic lymphohistiocytosis 10.2
31 thrombocytopenia 10.2
32 lymphocytic leukemia 10.2
33 cardiac tamponade 10.2
34 spondylitis 10.2
35 polyarteritis nodosa 10.2
36 leukemia, b-cell, chronic 10.2
37 methotrexate-associated lymphoproliferative disorders 10.2
38 folic acid deficiency anemia 10.2 MME TET2
39 central nervous system hematologic cancer 10.2 BCL6 MME
40 acute salpingitis 10.2 CXCL13 MME
41 nodular lymphocyte predominant hodgkin lymphoma 10.1 BCL6 PDCD1
42 lymphoma, mucosa-associated lymphoid type 10.1 BCL6 CXCL13 MME
43 cryoglobulinemia 10.1
44 thyroiditis 10.1
45 lymphosarcoma 10.1
46 orbit lymphoma 10.1 GZMB TIA1
47 lichen sclerosus et atrophicus 10.1 GZMB TIA1
48 lymphomatoid granulomatosis 10.1 GZMB TIA1
49 mature b-cell neoplasm 10.1 BCL6 MME
50 viral esophagitis 10.1 GZMB TIA1

Graphical network of the top 20 diseases related to Angioimmunoblastic T-Cell Lymphoma:



Diseases related to Angioimmunoblastic T-Cell Lymphoma

Symptoms & Phenotypes for Angioimmunoblastic T-Cell Lymphoma

UMLS symptoms related to Angioimmunoblastic T-Cell Lymphoma:


exanthema

MGI Mouse Phenotypes related to Angioimmunoblastic T-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.76 BCL6 CXCL13 ICOS ITK PDCD1 SYK
2 endocrine/exocrine gland MP:0005379 9.73 BCL6 ICOS ITK PDCD1 SYK TET2
3 immune system MP:0005387 9.65 BCL6 CXCL13 ICOS ITK MAF MME
4 liver/biliary system MP:0005370 9.02 BCL6 MME PDCD1 SYK TET2

Drugs & Therapeutics for Angioimmunoblastic T-Cell Lymphoma

Drugs for Angioimmunoblastic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-22-7, 2068-78-2 5978
4
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 1177-87-3
7
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
8
Ifosfamide Approved Phase 4,Phase 1,Phase 2,Early Phase 1 3778-73-2 3690
9
Epirubicin Approved Phase 4 56420-45-2 41867
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 53-03-2 5865
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 23214-92-8 31703
12
Mechlorethamine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 51-75-2 4033
13
Methotrexate Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
14
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
16
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 31703
17
Pirarubicin Investigational Phase 4 72496-41-4
18
Isophosphamide mustard Phase 4,Phase 1,Phase 2,Early Phase 1 0
19 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
20 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
26 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
27 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
30 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 BB 1101 Phase 4,Phase 3,Phase 2,Early Phase 1
33 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
35 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
37 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Folate Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Vitamin B9 Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
45
alemtuzumab Approved, Investigational Phase 3,Phase 1,Phase 2 216503-57-0
46
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
47
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
48 Orange Approved Phase 3
49
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
50
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613

Interventional clinical trials:

(show top 50) (show all 254)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
4 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
5 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
6 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
14 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
15 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
16 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
17 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
18 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
19 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
20 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
21 Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL Recruiting NCT03593018 Phase 3 Oral azacitidine;Romidepsin;Bendamustine;Gemcitabine
22 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Active, not recruiting NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
23 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
24 Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Not yet recruiting NCT03703375 Phase 3 Azacitidine;Romidepsin;Gemcitabine
25 Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma Unknown status NCT00958854 Phase 2 cyclophosphamide;fludarabine phosphate;thalidomide
26 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
27 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
28 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
29 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
30 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
31 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed NCT02273739 Phase 1, Phase 2 AG-221
32 A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Completed NCT00169156 Phase 2 Rituximab;Prednisone;Doxorubicine;Cyclophosphamide;Vincristine
33 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
34 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
35 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
36 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
37 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
38 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
39 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
40 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
41 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
42 506U78 in Treating Patients With Lymphoma Completed NCT00005080 Phase 2 nelarabine
43 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
44 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
45 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
46 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
47 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
48 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
49 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
50 Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma Completed NCT00039351 Phase 2 cyclophosphamide;prednisone;vincristine sulfate

Search NIH Clinical Center for Angioimmunoblastic T-Cell Lymphoma

Cochrane evidence based reviews: immunoblastic lymphadenopathy

Genetic Tests for Angioimmunoblastic T-Cell Lymphoma

Anatomical Context for Angioimmunoblastic T-Cell Lymphoma

MalaCards organs/tissues related to Angioimmunoblastic T-Cell Lymphoma:

41
T Cells, B Cells, Bone, Bone Marrow, Lymph Node, Endothelial, Liver

Publications for Angioimmunoblastic T-Cell Lymphoma

Articles related to Angioimmunoblastic T-Cell Lymphoma:

(show top 50) (show all 485)
# Title Authors Year
1
Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma. ( 29493850 )
2018
2
A four-year spontaneous remission of angioimmunoblastic T-cell lymphoma. ( 29048103 )
2018
3
Epstein-Barr virus clonality and plasmacytosis in a patient with atypical angioimmunoblastic T cell lymphoma. ( 29189897 )
2018
4
Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways. ( 29339730 )
2018
5
Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma. ( 29214764 )
2018
6
Florid Plasmacytosis in Angioimmunoblastic T Cell Lymphoma: A Diagnostic Conundrum. ( 29398831 )
2018
7
Hypercalcemia as a rare presentation of angioimmunoblastic T cell lymphoma: a case report. ( 29673407 )
2018
8
Secondary Cutaneous Epstein-Barr Virus-associated Diffuse Large B-cell Lymphoma with Hodgkin/Reed-Sternberg-like Cells in a Patient with Angioimmunoblastic T-cell Lymphoma. ( 29956714 )
2018
9
Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study. ( 29909754 )
2018
10
The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH. ( 29621877 )
2018
11
Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma. ( 29428971 )
2018
12
Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review. ( 29480865 )
2018
13
Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma. ( 29197996 )
2018
14
Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). ( 29966769 )
2018
15
Angioimmunoblastic T-cell lymphoma: a rare subtype of peripheral T-cell lymphoma. ( 29636953 )
2018
16
Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. ( 29662631 )
2018
17
Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing. ( 29981867 )
2018
18
Methotrexate-associated lymphoproliferative disorders with angioimmunoblastic T-cell lymphoma-like features accompanied by gamma-heavy chain disease in a patient with rheumatoid arthritis. ( 29987858 )
2018
19
EBV-related Diffuse Large B-cell lymphoma in a Patient with Angioimmunoblastic T Cell Lymphoma: A Case Presentation. ( 30066674 )
2018
20
Chylous ascites, anti-interferon-gamma autoantibody, and angioimmunoblastic T-cell lymphoma: a rare but intriguing connection over Mycobacterium avium. ( 30083859 )
2018
21
Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma. ( 30097855 )
2018
22
Angioimmunoblastic T-cell lymphoma presenting with extensive marrow plasmacytosis and hypergammaglobulinaemia: a diagnostic challenge. ( 30143343 )
2018
23
B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. ( 30150635 )
2018
24
Hemophagocytic lymphohistiocytosis presenting with annular erythema multiforme-like eruptions in a patient with angioimmunoblastic T cell lymphoma: A case report. ( 30186440 )
2018
25
Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr Virus positivity and its effects on clinicopathological features. ( 30240776 )
2018
26
Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. ( 30279227 )
2018
27
Cutaneous localization of angioimmunoblastic T-cell lymphoma may masquerade as B cell lymphoma or classical Hodgkin lymphoma: a histologic diagnostic pitfall. ( 30370547 )
2018
28
Angioimmunoblastic T-cell lymphoma mimicking diffuse large B-cell lymphoma. ( 30372708 )
2018
29
Antidiuretic hormone- and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion. ( 30485406 )
2018
30
Differentiation of angioimmunoblastic T-cell lymphoma from DRESS syndrome. ( 30557716 )
2018
31
Angioimmunoblastic T Cell lymphoma mimics reactive lymphoid tissue on cytomorphology: A multimodality approach utilising cytology, immunocytochemistry and flow cytometry to resolve this diagnostic dilemma. ( 28370552 )
2017
32
Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. ( 28148900 )
2017
33
A review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. ( 28889481 )
2017
34
Angioimmunoblastic T-Cell Lymphoma. ( 28340875 )
2017
35
Two cases of angioimmunoblastic T-cell lymphoma with concomitant positive serology for acute Epstein-Barr virus infection. ( 29071053 )
2017
36
Invasive aspergillosis in Refractory Angioimmunoblastic T cell lymphoma. ( 29129826 )
2017
37
Clinical characteristics of angioimmunoblastic T-cell lymphoma in China and C-reactive protein as an independent prognostic factor. ( 28953629 )
2017
38
A Rare Case of Angioimmunoblastic T-Cell Lymphoma with Epstein-Barr Virus-Negative Reed-Sternberg-Like B-Cells, Chylous Ascites, and Chylothorax. ( 28487786 )
2017
39
TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. ( 28337768 )
2017
40
Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma. ( 28194275 )
2017
41
Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells. ( 28543514 )
2017
42
Cardiac Tamponade as Initial Presentation of Angioimmunoblastic T-Cell Lymphoma. ( 28481741 )
2017
43
Angioimmunoblastic T-cell Lymphoma Associated with IgA Nephropathy. ( 28050005 )
2017
44
Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. ( 28832024 )
2017
45
Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. ( 28634614 )
2017
46
Angioimmunoblastic T-Cell Lymphoma: A Questionable Association with Follicular Dendritic Cell Sarcoma. ( 28197348 )
2017
47
Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome). ( 28611626 )
2017
48
Expression of Master Regulators of T-cell, Helper T-cell and Follicular Helper T-cell Differentiation in Angioimmunoblastic T-cell Lymphoma. ( 28943543 )
2017
49
Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. ( 29100307 )
2017
50
Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma. ( 29279549 )
2017

Variations for Angioimmunoblastic T-Cell Lymphoma

Cosmic variations for Angioimmunoblastic T-Cell Lymphoma:

9 (show top 50) (show all 146)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6498677 WDFY3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5163A>T p.L1721F 4:84765835-84765835 4
2 COSM6987215 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1625C>T p.P542L 16:2065544-2065544 4
3 COSM35978 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.811C>T p.R271* 6:137877081-137877081 4
4 COSM6498674 TLR6 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1828G>T p.D610Y 4:38827646-38827646 4
5 COSM6933803 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4075C>A p.R1359S 4:105269640-105269640 4
6 COSM4766127 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4133G>T p.C1378F 4:105269698-105269698 4
7 COSM4383952 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4519C>T p.Q1507* 4:105272900-105272900 4
8 COSM211617 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3061C>T p.Q1021* 4:105237003-105237003 4
9 COSM41741 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5618T>C p.I1873T 4:105276128-105276128 4
10 COSM5945065 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4553C>G p.S1518* 4:105275063-105275063 4
11 COSM87108 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2692G>T p.G898* 4:105236634-105236634 4
12 COSM5945026 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2233C>T p.Q745* 4:105236175-105236175 4
13 COSM4766169 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3500G>A p.R1167K 4:105241429-105241429 4
14 COSM6023745 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4707C>A p.Y1569* 4:105275217-105275217 4
15 COSM6023746 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3873G>A p.W1291* 4:105259688-105259688 4
16 COSM100058 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4333C>T p.Q1445* 4:105272714-105272714 4
17 COSM6023743 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5636A>G p.E1879G 4:105276146-105276146 4
18 COSM42037 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4210C>T p.R1404* 4:105272591-105272591 4
19 COSM6987361 SPEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.6073G>T p.E2025* 1:15932313-15932313 4
20 COSM1161155 SOCS1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4G>A p.V2I 16:11255475-11255475 4
21 COSM6987240 RET haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1759+1G>A p.? 10:43112964-43112964 4
22 COSM6987362 REL haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1077C>A p.Y359* 2:60920632-60920632 4
23 COSM6953464 PTPRT haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2353C>T p.L785F 20:42248703-42248703 4
24 COSM6023748 PLCG1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2606G>A p.G869E 20:41169482-41169482 4
25 COSM3734685 PLCG1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1034C>T p.S345F 20:41163944-41163944 4
26 COSM6916422 PIK3CG haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.220G>A p.V74M 7:106867781-106867781 4
27 COSM6987217 PAK5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1325C>A p.P442Q 20:9566050-9566050 4
28 COSM6498705 MIA3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5540C>A p.S1847* 1:222665435-222665435 4
29 COSM6987219 MED12 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4027C>A p.R1343S 23:71130194-71130194 4
30 COSM6498681 MDN1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1090G>T p.D364Y 6:89790167-89790167 4
31 COSM4169978 JAK1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3290G>A p.G1097D 1:64835475-64835475 4
32 COSM6498672 IFNAR2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.162G>A p.W54* 21:33245015-33245015 4
33 COSM33733 IDH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.515G>A p.R172K 15:90088606-90088606 4
34 COSM33732 IDH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.515G>T p.R172M 15:90088606-90088606 4
35 COSM33731 IDH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.514A>G p.R172G 15:90088607-90088607 4
36 COSM6987363 HIST1H3D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.383C>G p.A128G 6:26196868-26196868 4
37 COSM6987238 FAT1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3463G>T p.D1155Y 4:186663416-186663416 4
38 COSM6987239 FAT1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3463G>T p.D1155Y 4:186663416-186663416 4
39 COSM6987130 EGFR haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1939G>A p.A647T 7:55173002-55173002 4
40 COSM6498699 DYRK3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1288G>T p.V430L 1:206648591-206648591 4
41 COSM1304319 DOT1L haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2710G>A p.V904M 19:2220126-2220126 4
42 COSM6498709 DOCK10 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2701C>T p.P901S 2:224840027-224840027 4
43 COSM52944 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2645G>A p.R882H 2:25234373-25234373 4
44 COSM53042 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2644C>T p.R882C 2:25234374-25234374 4
45 COSM2911783 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1555-2A>G p.? 2:25244654-25244654 4
46 COSM6938921 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1279+1G>A p.? 2:25246619-25246619 4
47 COSM6987091 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.745C>T p.Q249* 2:25248147-25248147 4
48 COSM5944905 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2401A>G p.M801V 2:25239137-25239137 4
49 COSM4383603 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.915G>A p.W305* 2:25247690-25247690 4
50 COSM6498696 DHX9 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1885G>C p.E629Q 1:182876119-182876119 4

Expression for Angioimmunoblastic T-Cell Lymphoma

Search GEO for disease gene expression data for Angioimmunoblastic T-Cell Lymphoma.

Pathways for Angioimmunoblastic T-Cell Lymphoma

GO Terms for Angioimmunoblastic T-Cell Lymphoma

Biological processes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine production GO:0001816 8.96 ITK MAF
2 germinal center formation GO:0002467 8.62 BCL6 CXCL13

Molecular functions related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.62 ITK SYK

Sources for Angioimmunoblastic T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....